Diagnostic agent and therapeutic agent for pancreatic cancer

1. A method for diagnosing pancreatic cancer, wherein the method comprises:

reacting an anti-AMIGO2 antibody with a sample collected from the subject, wherein the sample is at least one sample selected from the group consisting of a pancreatic tissue sample, a blood sample, a serum sample, and a plasma sample;

detecting an AMIGO2 protein in the sample, and diagnosing pancreatic cancer when the level of AMIGO2 protein is higher in the sample than in a normal sample.

2. The method according to claim 1 , wherein the anti-AMIGO2 antibody binds to an extracellular region of the AMIGO2 protein.

3. The method according to claim 1 , wherein the anti-AMIGO2 antibody is labeled.

4. The method according to claim 1 , wherein the anti-AMIGO2 antibody is labeled with one or more labels selected from the group consisting of a biotin label, a fluorescent label, an enzyme label, a coenzyme label, a chemiluminescent label, and a radioactive isotope label.

5. The method according to claim 1 , wherein the anti-AMIGO2 antibody is labeled with or bound to a radioactive isotope.

6. The method according to claim 1 , wherein the anti-AMIGO2 antibody is labeled, and wherein the AMIGO2 protein is detected through diagnostic imaging.

7. The method according to claim 1 , wherein the anti-AMIGO2 antibody is labeled, and wherein the AMIGO2 protein is detected through diagnostic imaging with a liquid scintillator, an absorbance meter, or a luminometer.

8. The method according to claim 1 , wherein the sample is a pancreatic tissue sample.

9. The method according to claim 1 , wherein the sample is a blood sample.

10. The method according to claim 1 , wherein the sample is a serum sample.

11. The method according to claim 1 , wherein the sample is a plasma sample.